Alcon has reported sales of $1.76bn for the third quarter ended 30 September 2010 compared to $1.61bn for the same period in 2009.
Alcon has posted a net earnings of $446m for the third quarter 2010, or $1.47 per diluted share, compared to net earnings of $515m, or $1.71 per diluted share, for the comparable period in 2009.
Operating income was $495m, compared to $578m for the comparable period in 2009.
For the nine months ended 30 September 2010, Alcon has posted revenue of $5.37bn compared to $4.78bn for the year ago period.
For the nine months ended 30 September 2010, Alcon has posted a net earnings of $1.69bn, or $5.56 per diluted share, compared to $1.55bn, or $5.15 per diluted share, for the year ago period.
Operating income was $1.9bn, compared to $1.72bn for the year ago period.
Alcon president and CEO Kevin Buehler said that the company’s operational and financial performance in the third quarter clearly demonstrates their ability to combine their commercial capabilities and global scale to achieve sustainable organic growth.
“Once again, we have delivered high-quality results from our core operations, supplemented by strong growth from our recent acquisitions,” Buehler said.
Alcon is an eye care company which researches, develops, manufactures and markets surgical equipment and devices, pharmaceuticals, contacts lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye.